<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35418241</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-660X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical microbiology</Title>
          <ISOAbbreviation>J Clin Microbiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multicenter Clinical Evaluation of Modified Two-Tiered Testing Algorithms for Lyme Disease Using Zeus Scientific Commercial Assays.</ArticleTitle>
        <Pagination>
          <StartPage>e0252821</StartPage>
          <MedlinePgn>e0252821</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e02528-21</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/jcm.02528-21</ELocationID>
        <Abstract>
          <AbstractText>Modified two-tiered testing (MTTT) algorithms for Lyme disease (LD), which involve the sequential use of orthogonal enzyme immunoassays (EIAs) without immunoblotting, are acceptable alternatives to standard two-tiered testing (STTT; EIA followed by immunoblots) provided the EIAs have been FDA-cleared for this intended use. We evaluated four Zeus Scientific LD EIAs used in two distinct MTTT algorithms for FDA review. MTTT 1 used a VlsE1/pepC10 polyvalent EIA followed by a whole-cell sonicate (WCS) polyvalent EIA. MTTT 2 used the same first-tier EIA followed by separate IgM and IgG WCS EIAs. In a retrospective phase, we compared each MTTT algorithm to STTT using archived samples from LD patients or control subjects. In a prospective phase, we used the same algorithms to analyze consecutive excess samples submitted for routine LD serology to three clinical laboratories. For the retrospective phase, MTTTs 1 and 2 were more sensitive (56% and 74%) than STTT (41%; <i>P</i> ≤ 0.03) among 61 patients with acute erythema migrans (EM). In LD patients with neuroborreliosis, carditis, or arthritis (<i>n =</i> 75), sensitivity was comparable between algorithms (96 to 100%; <i>P</i> = 1.0). Among 190 control subjects without past LD, all algorithms were highly and comparably specific (≥99%, <i>P</i> = 0.48). For the prospective phase, (<i>n =</i> 2,932), positive percent-agreement (PPA), negative percent-agreement (NPA), and overall agreement of MTTT 1 with STTT were 93%, 97.7% and 97.4% (kappa 0.80). MTTT 2 yielded higher PPA (98%) but lower NPA (96.1%) and overall agreement (96.2%, kappa 0.74; all <i>P</i> &lt; 0.05). Compared with STTT, both MTTT algorithms provided increased sensitivity in EM patients, comparable sensitivity in later disease and non-inferior specificity.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Sfeir</LastName>
            <ForeName>Maroun M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>UConn Health, Farmington, Connecticut, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Meece</LastName>
            <ForeName>Jennifer K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Marshfield Clinicgrid.280718.4 Health System, Marshfield, Wisconsin, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Theel</LastName>
            <ForeName>Elitza S</ForeName>
            <Initials>ES</Initials>
            <Identifier Source="ORCID">0000-0002-6886-2294</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Granger</LastName>
            <ForeName>Dane</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fritsche</LastName>
            <ForeName>Thomas R</ForeName>
            <Initials>TR</Initials>
            <AffiliationInfo>
              <Affiliation>Marshfield Clinicgrid.280718.4 Health System, Marshfield, Wisconsin, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steere</LastName>
            <ForeName>Allen C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Branda</LastName>
            <ForeName>John A</ForeName>
            <Initials>JA</Initials>
            <Identifier Source="ORCID">0000-0002-6929-1219</Identifier>
            <AffiliationInfo>
              <Affiliation>Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Microbiol</MedlineTA>
        <NlmUniqueID>7505564</NlmUniqueID>
        <ISSNLinking>0095-1137</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025065" MajorTopicYN="Y">Borrelia burgdorferi</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005399" MajorTopicYN="N">Fishes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008193" MajorTopicYN="Y">Lyme Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012698" MajorTopicYN="N">Serologic Tests</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Borrelia</Keyword>
        <Keyword MajorTopicYN="N">Borrelia burgdorferi</Keyword>
        <Keyword MajorTopicYN="N">Lyme disease</Keyword>
        <Keyword MajorTopicYN="N">diagnostics</Keyword>
        <Keyword MajorTopicYN="N">immunodiagnostics</Keyword>
        <Keyword MajorTopicYN="N">serology</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare a conflict of interest. This study was funded by Zeus Scientific. J.A.B. has received research support for other studies from Pfizer, bioMerieux, Immunetics, Alere, DiaSorin, and the Bay Area Lyme Foundation (BALF) and has consulted for DiaSorin and Roche Diagnostics. E.S.T. has consulted for Euroimmune Inc. and Serimmune Scientific. T.R.F. and J.E.M. have received research support for other studies from bioMerieux, Immunetics and DiaSorin. TRF has consulted for DiaSorin. All other authors: No conflicts.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>10</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35418241</ArticleId>
        <ArticleId IdType="pmc">PMC9116174</ArticleId>
        <ArticleId IdType="doi">10.1128/jcm.02528-21</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Moore A, Nelson C, Molins C, Mead P, Schriefer M. 2016. Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of Lyme disease, United States. Emerg Infect Dis
22:1169–1177. doi:10.3201/eid2207.151694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid2207.151694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CDC. 1995. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep
44:590–591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7623762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branda JA, Body BA, Boyle J, Branson BM, Dattwyler RJ, Fikrig E, Gerald NJ, Gomes-Solecki M, Kintrup M, Ledizet M, Levin AE, Lewinski M, Liotta LA, Marques A, Mead PS, Mongodin EF, Pillai S, Rao P, Robinson WH, Roth KM, Schriefer ME, Slezak T, Snyder J, Steere AC, Witkowski J, Wong SJ, Schutzer SE. 2018. Advances in serodiagnostic testing for Lyme disease are at hand. Clin Infect Dis
66:1133–1139. doi:10.1093/cid/cix943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cix943</ArticleId>
            <ArticleId IdType="pmc">PMC6019075</ArticleId>
            <ArticleId IdType="pubmed">29228208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branda JA, Steere AC. 2021. Laboratory diagnosis of Lyme borreliosis. Clin Microbiol Rev
34:e00018-19. doi:10.1128/CMR.00018-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CMR.00018-19</ArticleId>
            <ArticleId IdType="pmc">PMC7849240</ArticleId>
            <ArticleId IdType="pubmed">33504503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pegalajar-Jurado A, Schriefer ME, Welch RJ, Couturier MR, MacKenzie T, Clark RJ, Ashton LV, Delorey MJ, Molins CR. 2018. Evaluation of modified two-tiered testing algorithms for Lyme disease laboratory diagnosis using well-characterized serum samples. J Clin Microbiol
56:e01943-17. doi:10.1128/JCM.01943-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01943-17</ArticleId>
            <ArticleId IdType="pmc">PMC6062810</ArticleId>
            <ArticleId IdType="pubmed">29743307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB, Nowakowski J, Marques A, Johnson BJ, Dumler JS. 2013. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis
75:9–15. doi:10.1016/j.diagmicrobio.2012.09.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diagmicrobio.2012.09.003</ArticleId>
            <ArticleId IdType="pmc">PMC4052829</ArticleId>
            <ArticleId IdType="pubmed">23062467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ. 2011. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis
53:541–547. doi:10.1093/cid/cir464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cir464</ArticleId>
            <ArticleId IdType="pubmed">21865190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molins CR, Delorey MJ, Replogle A, Sexton C, Schriefer ME. 2017. Evaluation of bioMerieux’s dissociated VIDAS Lyme IgM II (LYM) and IgG II (LYG) as a first-tier diagnostic assay for Lyme disease. J Clin Microbiol
55:1698–1706. doi:10.1128/JCM.02407-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.02407-16</ArticleId>
            <ArticleId IdType="pmc">PMC5442525</ArticleId>
            <ArticleId IdType="pubmed">28330884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branda JA, Strle K, Nigrovic LE, Lantos PM, Lepore TJ, Damle NS, Ferraro MJ, Steere AC. 2017. Evaluation of modified 2-tiered serodiagnostic testing algorithms for early Lyme disease. Clin Infect Dis
64:1074–1080. doi:10.1093/cid/cix043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cix043</ArticleId>
            <ArticleId IdType="pmc">PMC5399943</ArticleId>
            <ArticleId IdType="pubmed">28329259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molins CR, Delorey MJ, Sexton C, Schriefer ME. 2016. Lyme borreliosis serology: performance of several commonly used laboratory diagnostic tests and a large resource panel of well-characterized patient samples. J Clin Microbiol
54:2726–2734. doi:10.1128/JCM.00874-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.00874-16</ArticleId>
            <ArticleId IdType="pmc">PMC5078550</ArticleId>
            <ArticleId IdType="pubmed">27558183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis IRC, McNeil SA, Allen W, MacKinnon-Cameron D, Lindsay LR, Bernat K, Dibernardo A, LeBlanc JJ, Hatchette TF. 2020. Performance of a modified two-tiered testing enzyme immunoassay algorithm for serologic diagnosis of Lyme Disease in Nova Scotia. J Clin Microbiol
58:e01841-19. doi:10.1128/JCM.01841-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01841-19</ArticleId>
            <ArticleId IdType="pmc">PMC7315017</ArticleId>
            <ArticleId IdType="pubmed">32321781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baarsma ME, Schellekens J, Meijer BC, Brandenburg AH, Souilljee T, Hofhuis A, Hovius JW, van Dam AP. 2020. Diagnostic parameters of modified two-tier testing in European patients with early Lyme disease. Eur J Clin Microbiol Infect Dis
39:2143–2152. doi:10.1007/s10096-020-03946-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10096-020-03946-0</ArticleId>
            <ArticleId IdType="pmc">PMC7561539</ArticleId>
            <ArticleId IdType="pubmed">32632699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branda JA, Lemieux JE, Blair L, Ahmed AA, Hong DK, Bercovici S, Blauwkamp TA, Hollemon D, Ho C, Strle K, Damle NS, Lepore TJ, Pollock NR. 2021. Detection of Borrelia burgdorferi cell-free dna in human plasma samples for improved diagnosis of early Lyme borreliosis. Clin Infect Dis
73:e2355–e2361. doi:10.1093/cid/ciaa858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa858</ArticleId>
            <ArticleId IdType="pmc">PMC8492203</ArticleId>
            <ArticleId IdType="pubmed">32584965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mead P, Petersen J, Hinckley A. 2019. Updated CDC recommendation for serologic diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep
68:703. doi:10.15585/mmwr.mm6832a4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15585/mmwr.mm6832a4</ArticleId>
            <ArticleId IdType="pmc">PMC6818702</ArticleId>
            <ArticleId IdType="pubmed">31415492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molins CR, Sexton C, Young JW, Ashton LV, Pappert R, Beard CB, Schriefer ME. 2014. Collection and characterization of samples for establishment of a serum repository for Lyme disease diagnostic test development and evaluation. J Clin Microbiol
52:3755–3762. doi:10.1128/JCM.01409-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.01409-14</ArticleId>
            <ArticleId IdType="pmc">PMC4187768</ArticleId>
            <ArticleId IdType="pubmed">25122862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Landis JR, Koch GG. 1977. The measurement of observer agreement for categorical data. Biometrics
33:159–174. doi:10.2307/2529310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2307/2529310</ArticleId>
            <ArticleId IdType="pubmed">843571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fawcett PT, Gibney KM, Rose CD, Dubbs SB, Doughty RA. 1992. Frequency and specificity of antibodies that crossreact with Borrelia burgdorferi antigens. J Rheumatol
19:582–587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1593581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, White JL, Mead PS. 2014. Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis
59:676–681. doi:10.1093/cid/ciu397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciu397</ArticleId>
            <ArticleId IdType="pmc">PMC4646413</ArticleId>
            <ArticleId IdType="pubmed">24879782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binnicker MJ, Jespersen DJ, Harring JA, Rollins LO, Bryant SC, Beito EM. 2008. Evaluation of two commercial systems for automated processing, reading, and interpretation of Lyme borreliosis Western blots. J Clin Microbiol
46:2216–2221. doi:10.1128/JCM.00200-08.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.00200-08</ArticleId>
            <ArticleId IdType="pmc">PMC2446909</ArticleId>
            <ArticleId IdType="pubmed">18463211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kadkhoda K, Gretchen A. 2018. Higher sensitivity of the recom line Borrelia IgG Immunoblot Kit than of the standard Lyme IgG Immunoblot Kit according to CDC testing criteria. J Clin Microbiol
56:e00527-18. doi:10.1128/JCM.00527-18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.00527-18</ArticleId>
            <ArticleId IdType="pmc">PMC6062798</ArticleId>
            <ArticleId IdType="pubmed">29875190</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
